<DOC>
	<DOC>NCT01743157</DOC>
	<brief_summary>A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).</brief_summary>
	<brief_title>Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma</brief_title>
	<detailed_description>A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy (Temodar,Cisplatin, Velban,IL2 and IFN)plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable disease 2. Age 1870 years old 3. Adequate pulmonary and cardiac function for highdose IL2 4. PS 02 5. Previous ipilimumab therapy will not exclude patients, but patients with previous ipilimumab will have separate efficacy analysis 1. Brain metastases 2. Creatinine &gt; 2x ULN; bilirubin &gt; 3, WBC &lt; 3500, Platelets &lt; 100,000, Hgb &lt; 9 3. Another active malignancy 4. Gastrointestinal tract metastases except rectal metastases or primary are allowable 5. Previous therapy for metastatic disease with chemotherapy of duration over 3 months or with highdose interleukin2 6. History of colitis or autoimmune disease such as lupus or rheumatoid arthritis 7. Bevacizumabrelated contraindications: Hemoptysis or history of severe bleeding, uncontrolled hypertension, proteinuria with protein/creatinine ratio &gt; 1, acute myocardial infarction within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>